These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 19871154)

  • 41. Hypothesis--the natural selection of psoriasis.
    McFadden JP
    Clin Exp Dermatol; 1990 Jan; 15(1):39-43. PubMed ID: 2311279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transfer of delayed hypersensitivity to diphtheria toxin in man.
    LAWRENCE HS; PAPPENHEIMER AM
    J Exp Med; 1956 Sep; 104(3):321-35. PubMed ID: 13357688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Scarlet fever is caused by a limited number of Streptococcus pyogenes lineages and is associated with the exotoxin genes ssa, speA and speC.
    Silva-Costa C; Carriço JA; Ramirez M; Melo-Cristino J
    Pediatr Infect Dis J; 2014 Mar; 33(3):306-10. PubMed ID: 24168973
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Study of the immunological and epidemiological activity of purified sorbed scarlet fever toxin].
    MITEL'MAN SL
    Zh Mikrobiol Epidemiol Immunobiol; 1960 Aug; 31():70-5. PubMed ID: 13771373
    [No Abstract]   [Full Text] [Related]  

  • 45. Proof for the lack of diphtheria toxin in culture filtrates of Corynebacterium ulcerans strain ATCC 9015.
    Vertiev YuV ; Ezepchuk YuV ; Souckova A; Soucek A
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 249(4):520-6. PubMed ID: 6797150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regional differences in historical diphtheria and scarlet fever notification rates in The Netherlands, 1905-1925: a spatial-temporal analysis.
    McDonald SA; van Wijhe M; de Melker H; van Meijeren D; Wallinga J
    R Soc Open Sci; 2023 Nov; 10(11):230966. PubMed ID: 38034127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Temporal variation in bacterial disease frequency: molecular population genetic analysis of scarlet fever epidemics in Ottawa and in eastern Germany.
    Musser JM; Nelson K; Selander RK; Gerlach D; Huang JC; Kapur V; Kanjilal S
    J Infect Dis; 1993 Mar; 167(3):759-62. PubMed ID: 8440944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Scarlet fever and types of erythrogenic toxins produced by the infecting streptococcal strains.
    Knöll H; Srámek J; Vrbová K; Gerlach D; Reichardt W; Köhler W
    Zentralbl Bakteriol; 1991 Dec; 276(1):94-106. PubMed ID: 1789905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increase of emm1 isolates among group A Streptococcus strains causing scarlet fever in Shanghai, China.
    Chen M; Cai J; Davies MR; Li Y; Zhang C; Yao W; Kong D; Pan H; Zhang X; Zeng M; Chen M
    Int J Infect Dis; 2020 Sep; 98():305-314. PubMed ID: 32562850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suitability of the Vero cell method for titration of diphtheria antitoxin in the United States potency test for diphtheria toxoid.
    Gupta RK; Higham S; Gupta CK; Rost B; Siber GR
    Biologicals; 1994 Mar; 22(1):65-72. PubMed ID: 8068315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Managing scarlet fever.
    Drug Ther Bull; 2017 Sep; 55(9):102. PubMed ID: 28882851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The association between varicella (chickenpox) and group A streptococcus infections in historical perspective.
    Coleman S
    SAGE Open Med; 2016; 4():2050312116658909. PubMed ID: 27504182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. STUDIES ON THE BIOLOGY OF STREPTOCOCCUS : III. AGGLUTINATION AND ABSORPTION OF AGGLUTININ WITH STREPTOCOCCUS SCARLATINAE.
    Stevens FA; Dochez AR
    J Exp Med; 1924 Jul; 40(2):253-63. PubMed ID: 19868913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of the shuffling of Streptococcus pyogenes clones and the fluctuation of scarlet fever cases between 2000 and 2006 in central Taiwan.
    Chiou CS; Wang YW; Chen PL; Wang WL; Wu PF; Wei HL
    BMC Microbiol; 2009 Jun; 9():115. PubMed ID: 19486515
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Occurrence of antigenically diverse toxin of beta hemolytic Streptococci in scarlet fever].
    ZAHRADNICKY J; SLAVIK R
    Cesk Epidemiol Mikrobiol Imunol; 1953 Aug; 2(4):264-9. PubMed ID: 13209652
    [No Abstract]   [Full Text] [Related]  

  • 56. The incidence of scarlet fever.
    Perks EM; Mayon-White RT
    J Hyg (Lond); 1983 Oct; 91(2):203-9. PubMed ID: 6358344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Active immunization against scarlet fever. II. Desensitization with streptococcal toxin as a method of detection of scarlet fever toxin in a mixture with antibiotics].
    VOLOVICH NI; PEDENKO AI
    Zh Mikrobiol Epidemiol Immunobiol; 1954 Mar; 3():35. PubMed ID: 13157583
    [No Abstract]   [Full Text] [Related]  

  • 58. [Comparative efficacy of homologous and heterologous biologicals against diphtheria].
    Kapustian VA; Matokhina AG; Perelygina OV
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):94-6. PubMed ID: 20465009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [CLINICAL EXPERIENCE WITH VACCINATIONS].
    ZISCHINSKY H
    Wien Med Wochenschr; 1964 May; 114():329-34. PubMed ID: 14232729
    [No Abstract]   [Full Text] [Related]  

  • 60. Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study.
    Lamagni T; Guy R; Chand M; Henderson KL; Chalker V; Lewis J; Saliba V; Elliot AJ; Smith GE; Rushton S; Sheridan EA; Ramsay M; Johnson AP
    Lancet Infect Dis; 2018 Feb; 18(2):180-187. PubMed ID: 29191628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.